NetScientific is a biomedical and transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

Sound Energy is a well-funded African and European upstream gas company, listed on AIM, with a recent significant discovery in Morocco, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and a potentially transformational drill programme.

We are pursuing an onshore gas strategy underpinned by strong European gas fundamentals, which is proving very robust to the current oil price environment and to an increasingly carbon-conscious world (where gas is, rightly, seen as a cleaner alternative to coal and oil).

ThinCats are one of the pioneers of the peer-to-peer business lending industry; specialising in loans with security and linking retail and institutional investors directly with established business borrowers to provide a serious alternative to high street banks. The company was founded in the aftermath of the global financial crisis, with the aim of offering loans to UK businesses struggling to access funding through traditional channels, whilst providing investors with attractive rates of interest unavailable through many conventional investment portfolios.

A key element of the ThinCats’ ethos has always been to avoid the algorithm-led decision making often used by banks; the founders were keen to hear the stories behind the borrowers’ investment needs, and assess each one based on its merits. The company continues to work in this way, harnessing the knowledge of financial experts to assess each loan application, thereby encouraging growth, development and innovation in UK business.

Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London.

PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges.  Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares.

Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment.  To date over £52m has been sourced via the platform.

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

·         Early detection of cancer;

·         Personalised cancer treatment;

·         Monitoring of cancer patients during treatment; and

·         Post-treatment monitoring of cancer patients in remission.

Avation PLC is a commercial passenger aircraft leasing company that was incorporated in England and Wales in 2006 and whose shares are admitted to the standard segment of the UK listing authority's official list and are traded on the Main Market of the London Stock Exchange (LSE: AVAP).

Avation owns and manages a fleet of aircraft which it leases, through its subsidiaries, to airlines across the world. Our customers include Flybe, Virgin Australia, Thomas Cook, Condor, Air France, easyJet, Eva Air, Philippine Airlines, Air India, Vietjet Air, Fiji Airways and Mandarin Airlines. The company’s fleet includes Airbus A320 family aircraft as well as Fokker 100s and ATR 72s.

Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.

First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.

This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.

First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.